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ABSTRACT

Insulin-like growth factor binding protein-6 (IGFBP-6), a component of the stem cell
niche involved in the differentiation of skeletal muscle myogenesis, is expressed in
developing muscle cells and is the main regulator of IGF-II. In this study, I investigated
the role of IGFBP-6 in the commitment of skeletal muscle derivation from placenta
mesenchymal stem cells (PMSCs). I hypothesized that IGFBP-6 inhibits the temporal
maintenance of PMSCs and promotes the differentiation of PMSCs into muscle via both
extracellular and intracellular mechanisms. PMSCs can differentiate into muscle cells
expressing the muscle markers Pax3/7, MyoD, and Myogenin with the formation of
multi-nucleated fibers. Under differentiation conditions, silencing IGFBP-6 increased
Pax3/7 and decreased OCT4 levels. In contrast, under non-differentiation conditions,
there was a significant increase in Pax3/7 levels at day 7 with intracellular and
extracellular increase of IGFBP-6, similarly silencing IGFBP-6 under non-differentiation
conditions significantly increased Pax3/7 at 24 hours and decreased OCT4 levels over
time same as in differentiation conditions. I concluded that increasing lGFBP-6 promotes
PMSCs differentiation with more prominent effects at the beginning of the differentiation
process, while silencing IGFBP-6 has more dramatic effects on PMSCs. Knowledge of
the effects of IGFBP-6 on muscle differentiation will help improve strategies for skeletal
muscle regeneration therapies using stem cells.

KEYW ORDS

Placental mesenchymal stem cell, IGFBP-6, muscle differentiation, Pax3/7, OCT4,
MyoD, Myogenin.
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1.0 INTRODUCTION
1.1 Stem Cells
1.1.1 Overview

Stem cells possess two distinctive characteristics, namely a) the ability to self-renew
through mitotic divisions undergoing symmetric division, and b) the ability to
differentiate into a diverse range of cells through asymmetric divisions (1). Pluripotency
is the fundamental characteristic of stem cells, and based on its developmental potential,
it can be categorized into three types - totipotent, pluripotent, or multipotent (2).
Totipotent stem cells can give rise to all embryonic (including germ cells) as well as
extraembryonic cell types. Pluripotent stem cells are descendants of totipotent cells and
can give rise to cell types of all three germ layers (3). In contrast, multipotent stem cells
can only produce a closely related family of cells or lineage, usually from one germ layer
(4).

Research on stem cells has been performed mainly on two types - embryonic stem cells
(ES) which are derived from the inner cell mass of early embryos at the blastocyst
developmental stage (5), or adult stem cells which are derived from tissues from later
fetal gestational stage or adult (4). The major difference between these two types is the
ability to differentiate: Embryonic stem cells (ES) are pluripotent and can differentiate
into most cell types in the body (3), whereas adult stem cells, sometimes called
mesenchymal stem cells (MSCs), are multipotent cells and have more limited
differentiation abilities (lineage specific tissue) (4).
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Research on stem cells has progressed greatly in recent years and the hope of using stem
cells in tissue regeneration and cellular therapies is becoming more possible due to the
increased amount of knowledge (7, 8). However, before stem cells can be used reliably
and safely in regenerative medicine, it is essential to understand how factors within the
stem cell microenvironment influence stem cell differentiation and self-renewal as stem
cell fate is easily altered by the culture conditions (9).
1.1.2 Em bryonic Stem (ES) Cells

The first line of mouse ES cells was first reported in 1981 (10); however the derivation of
human ES cell lines from blastocysts was not reported until 1998 (5). ES cells are
unspecialized cells with nearly unlimited self-renewal capacity (11). Moreover, ES cells
possess pluripotency which is an essential characteristic for the stem cell state (12).
Furthermore, ES cells differentiate, in vivo, into cell types from all three germ layers
(ectoderm, mesoderm, and endoderm) (13).
1.1.3 Induced Pluripotent Stem (iPS) Cells

s

Induced pluripotent stem cells (iPS) using transcription factor-based reprogramming
demonstrated ES cell properties including ES cell morphology, expression of ES marker
genes, high proliferation rate, and teratoma formation (14,15).
In 2006, the transcription factor-based reprogramming began, when mouse fibroblasts
were reprogrammed by retroviral introduction of transcription factors OCT-4, SOX-2,
KLF-4, and c-MYC (16). Moreover, in a 2009 study by Kim et al, it was shown that the
expression of OCT-4 alone could induce the reprogramming of human adult neural stem
cells (17).
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1.1.3.1 Stem Ceil Pluripotency

The main transcription factors that regulate pluripotency are OCT4, SOX2, and NANOG
(15, 16, 17). These factors either cooperate together or function alone to promote stem
cell pluripotency and inhibit cell differentiation (18).
In stem cells, OCT4, a member of the POU homeodomain protein family, is a
transcription factor that is integral for pluripotent ES cells and is used as a marker of
pluripotency but is not sufficient to maintain ES cells in the undifferentiated state (19).
OCT4 regulates pluripotent gene expression by repressing genes involved in
differentiation and development (19). Moreover, the down-regulation of OCT4 is
associated with differentiation, where terminally differentiated cells lose the ability to
express OCT4 (20). Furthermore, OCT4 is considered the “master regulator” of
pluripotency (17).OCT4 expression is shown in numerous human adult stem cell types,
including hematopoietic (21), liver (22), pancreatic (22), gastric (22), and mesenchymal
stem cells (22,23).
1.1.4 Adult M esenchymal Stem Cells (MSCs)

The first report of the presence of adult stem cells was in 1961 by Canadian scientists
McCulloch and Till (24). Bone marrow MSCs were the first to be isolated in 1968 by
Friedenstein (25). To define the MSC population in vitro, the International Society for
Cellular Therapy established three criteria, namely that a MSC must be a) plasticadherent when maintained in standard culture conditions, b) express CD 105 (a stromal
and vascular marker), CD73, and CD90 (fibroblast markers) and lack hematopoietic
markers such as CD45 and CD34, and c) be capable of differentiation into osteoblasts,
adipocytes, and chondroblasts (3).
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Although traditionally isolated from bone marrow (26), more recent reports have
described the isolation of cells with MSC characteristics from other mature organs and
tissues such as skeletal muscle (27), adipose tissue (28), deciduous teeth (29), umbilical
cord (30) and peripheral blood (31), fetal liver and lung, amniotic fluid, synovium and the
circulatory system (32). In culture, MSCs are defined as plastic-adherent, fibroblast-like
cells which are able to self-renew and differentiate into different mesodermal cell lineages
including bone, adipose and cartilage tissue (3).
Moreover, MSCs are very important candidates for regenerative medicine because most
adult tissues possess multipotent MSCs, which are crucial for tissue maintenance and
repair (33). Also in contrast to ESC, human MSCs have been studied in phase 1 and 2
clinical trials with the possibility of being used in the clinic in the very near future (32).
1.1.4.1 Placental M esenchymal Stem Cells (PM SCs)

The placenta is a vital organ for the embryo, acting as the interface between the fetal and
maternal environments (34) unlike the early embryo from which embryopic stem cells are
derived, the placenta is a non-controversial source of adult mesenchymal stem cells
(PMSCs) and is a readily available source o f MSCs for possible tissue regeneration
therapy for human patients (5 36,37).
The embryonic mesenchymal cells infiltrate the cytotrophoblast layer at 6-7 days post
fertilization, where these cells in conjunction with trophoblast stem cells, invade the
maternal endometrium for implantation and initiation of placental development (38, 39).
The main functional units of the placenta are the chorionic villi, which carry the
embryonic blood and allow the fetal-maternal exchange (40). Moreover, stem cells
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derived from the chorionic villi have greater cell expansion compared to the adult bone
marrow MSCs (41).
Previous studies from our laboratory have demonstrated that placental mesenchymal stem
cells isolated from the chorionic villi express markers common to mesenchymal stem
cells including CD105 (a stromal and vascular marker), CD73, and CD90 (fibroblast
markers), and lack the hematopoietic markers CD34, CD45 and CD14 (42, 43). In
addition, PMSCs exhibit ESC surface markers SSEA-4, TRA-1-61, and TRA-1-80 (44).
Adipogenic, osteogenic, myogenic and neurogenic differentiation is achieved after
culturing PMSCs under the appropriate culture or niche conditions (42, 44,45). All of the
above indicate that stem cells isolated from the placenta achieve MSC criteria. Therefore,
PMSCs could provide an ethical and readily available source of multipotent stem cells for
future experimental and clinical applications (46).
In this study, cells previously obtained from preterm placental tissue (13-weeks) and
representative o f late first trimester pregnancy, and characterized, extensively for
mesenchymal stem cell markers and differentiation ability in the Han laboratory, were
used.
1.2 Stem Cell M icroenvironm ent

The stem cell microenvironment or “niche” hypothesis was developed in 1978 by
Schofield, who proposed that stem cells reside within fixed niches that maintain stem cell
properties (47). The stem cell microenvironment is an anatomical structure, including
cellular and non-cellular components which integrate local and systemic factors to
regulate stem cell proliferation, differentiation, survival and localization (48).
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Proliferation and differentiation of stem cells are maintained by the surrounding
microenvironment, sustaining a healthy proliferative state via several clues including
physical, structural, neural, paracrine, autocrine, and metabolic interactions (49). A
combination of different micro-environmental signals would regulate the state of stem
cells to either be proliferative or quiescencent depending on the active process of tissue
regeneration (48).
1.2.1 Niche Components

The components present in the microenvironment, such as growth factors, cytokines,
extracellular matrices, chemokines and oxygen levels, are critical for limiting or
facilitating MSC survival and propagation to self-like cells (symmetric division) or to
more specialized committed cells (asymmetric division) (47). Therefore, regulation of
such factors would change the proliferative state of stem cells. Moreover, stem cells
grown in culture are also affected by cell plating density, passage number, and surface
quality.
\

Insulin-like growth factors are the early effectors that impact cell fate; therefore,
controlling the availability of growth factors in the stem cell microenvironment is
beneficial for manipulating stem cells in vitro. This study will focus on the effects of
insulin like growth factors (IGFs) and their binding proteins (IGFBPs), IGFBP-6 in
particular, as components of the stem cell niche (Figure 1).
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Figure 1: Schematic of the stem cell microenvironment.
Cells grown in culture are influenced by many factors from the microenvironment; these
components present in the microenvironment, such as growth factors, cytokines,
extracellular matrices, chemokines and oxygen levels, are critical for limiting or enabling
the MSCs proliferation and differentiation.
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1.3 Insulin-like Growth Factor (IGF) System

The insulin-like growth factor (IGF) system is a complex super-family that has been
shown to regulate cell growth, differentiation and the maintenance of cell survival
through several mitogen activation cascades. The insulin-like growth factor family has
been shown to be one of the most important paracrine/autocrine growth factors that
regulate fetal and placental growth and development Several studies have also
demonstrated the importance of the IGF system in cancer development (50, 51) and some
cancer therapies are targeted against the mitogenic actions of this system (52, 53).
Whether the therapies target adult stem cells that develop cancer cells is unknown.
This super-family includes the IGF peptides IGF-I and IGF-II, the cell surface receptors
type I (IGF-IR) and type II (IGF-IIR) receptors, and the IGF binding proteins (IGFBPs)
IGFBP-1 through IGFBP-6 (Figure 2).
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Figure 2: Insulin-like growth factor superfamily.
The IGF superfamily consists of IGF peptides IGF-I and IGF-II; the cell surface receptors
IGF-ER. and IGF-IIR; and the IGF binding proteins (IGFBPs).

I6FBP-1 IGFBP-2 IGFBP-3 IGFBP-4 IGFBP-5 IGFBP-6

IGF-I

IGF-II

Cell growth,
differentiation, survival
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1 3 .1

Insulin-like Growth Factor-1 and -11

Insulin-like growth factors are critical for fetal and placental development (34), with
important roles in tissue repair (54), and tumorigenesis (55).Insulin-like growth factor
(IGF-I) and (IGF-II), are highly homologous 70 and 67 amino acid single-chain
polypeptides, respectively, with structural similarities to pro-insulin. They are circulating
peptides that act as potent mitogens (56), effects mediated by binding to the IGF-IR, a
membrane receptor shown to have tyrosine kinase activity. IGF peptides stimulate amino
acid uptake, increase cell proliferation and promote cell differentiation (57). These
actions are carried out through interactions with the IGF receptors and the actions of the
IGF binding proteins.
Since the discovery of IGFs in the late 1950’s, it is clear that these peptides can induce
and mediate a variety of cellular responses including survival, growth, proliferation, and
differentiation (55, 58, 59). It is also known that IGFs are produced locally within almost
all tissues for autocrine and paracrine effects, but circulating IGFs are mainly produced
by the liver for endocrine functions (60). Although IGF levels decrease with age, the IGF
system continues to regulate cells throughout adulthood (61).
13.1.1 IGFs in Placental Development

IGF-I and -II are both present in the human placenta as early as 6 weeks gestation (62).
While IGF-I is involved in enabling nutrient exchange in the placenta, IGF-II increases
the total surface area for gas exchange between the mother and the fetus in the placenta
(63, 64, 65). Inhibition studies for IGF-I and IGF-II demonstrated that both peptides are
important for placental development as they enhance placenta derived fibroblast
proliferation and survival (66, 67). IGFs and the IGF system are vital for placental
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development as they regulate the function and growth of placental cells, and therefore are
important for regulating PMSC fate.
1.3.2

Insulin-like Growth Factor Type-I and - I I Receptors

The biological actions of the IGFs are mediated through two types of IGF receptors (67).
IGF-IR is a member of receptor tyrosine-kinases (RTKs) family of cell surface receptors
and was originally isolated from human placenta (68). Most of the mitogenic actions of
the insulin-like growth factors are mediated by the IGF-IR, which can bind IGF-I, IGF-II
and insulin, but binds IGF-I with highest affinity (2-3 fold higher than IGF-II, and 1001000 fold higher than insulin) (55,60).
IGF-IR is a trans-membrane tetramer receptor that exists as dimers composed of two el
and two P-subunits linked by disulfide bonds. The extracellular a-subunits bind the
ligand, whereas the two catalytic P-subunits possess tyrosine kinase activity (67). Upon
activation of the extracellular a subunits of the IGF-IR by ligand binding, activation and
deactivation o f intracellular adaptor proteins (IRS-1), SHC (Src homology 2 domaincontaining transforming protein C l), GRB2 (Growth factor receptor-bound protein 2),
p85 (regulatory subunit for PI3K), and Src kinase (tyrosine kinase) proteins will take
place (67, 68). IGF-IR initiates the activation of two main signal transduction pathways
through IRS-1 and SHC proteins, which are: a) phosphatidylinositol 3-kinase (PI3K) that
is activated by IRS-1 that activates p85 which targets AKT, a serine/threonine kinase, by
phosphorylation at specific sites, to promote cell survival and proliferation (69, 70), and
b) mitogen-activated protein kinases (MAPK) which are activated by phosphorylated
SHC which activates GRB2 complexes to activate Ras GTP-binding protein that leads to
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the recruitment of the extracellular signal-regulated kinase 1 and 2 (Erkl/2) resulting in
differentiation (58, 69,71) (Figure 3).
Therefore, a crosstalk between different RTKs and their ligands can lead to different
responses and outcomes. Moreover, the availability of target effectors and the period of
their activation are of high importance in determining cell fate decisions for committing
either to proliferation or differentiation (72). It was reported by Marshall et al., that a
prolonged activation of Erkl/2, which allows the translocation of Erkl/2 into the nucleus,
leads to differentiation; whereas a transient activation of Erkl/2 leads to proliferation and
is not sufficient to elevate the levels of nuclear Erkl/2 (73). Therefore, the type and the
availability of growth factors in the microenvironment plays an important role in
determining stem cell fate.
On the other hand, the IGF-IIR or cation-dependent mannose 6-phosphate (Man-6-P)
receptor is a monomeric transmembrane receptor that is not mitogenic. The IGF-IIR does
not bind insulin, but can bind man-6-P, IGF-II, and IGF-I, with a 500-fold higher affinity
%

for IGF-II than IGF-I (74); and it does not have tyrosine kinase activity and does not
transduce a signaling cascade but it can control IGF-II availability (75,76).
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Figure 3: Schematic o f the IG F-IR signaling pathway.

Insulin-like growth factor I (IGF-I) and insulin-like growth factor II (IGF-II) binding to
the insulin-like growth factor receptor (IGF-IR) activate its intrinsic tyrosine kinase
activity resulting in signaling through cellular pathways that stimulates proliferation
and/or differentiation. The key downstream signaling pathways include PI3K-Akt-mTOR
and the Raf-MEK-ERK (MAPK) pathway.
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1.3.3

Insulin-like Growth Factor Binding Proteins

Six IGF specific binding proteins, IGFBP-1 through -6, are soluble ~30 kDa binding
proteins which serve as modulators of IGF activity through direct binding. Under normal
physiological conditions IGFs bind IGFBPs with greater affinity than they bind IGF-IRs
(77, 78, 79). IGFBPs are the carriers for IGFs in the circulation, through non-covalent
binding (80), protecting them from degradation (81, 82), and delivering them to specific
tissues. Thus, IGFBPs modulate the biological actions of IGFs. Also, IGFBPs increase the
half-life o f the IGF peptides in the circulation and control peptide access to the IGF-IR,
thus playing an important role in IGF-regulated cell metabolism, development, and
growth (72). In recent years, it has become apparent that the IGFBPs can be expressed
and maintained within the cellular environment and have functions independent of
regulating IGF (83). One such IGFBP is IGFBP-6.
1.3.4

Insulin-like Growth Factor Binding Protein-6 (IGFBP-6)

IGFBP-6 is a 30 kDa, secreted, O-linked glyco protein, which unlike other IGFBPs has a
significantly higher affinity (100 fold), for IGF-II than IGF-I (83, 84). IGFBP-6 has three
structural domains - the C terminal domain, the L domain (for linker or labile) and the N
terminal domain. The C-terminal domain of IGFBP-6 shows a high degree of mobility.
Interestingly, the site on IGF-II where IGFBP-6 binds overlaps with that of the IGF-IR
binding site, giving a structural basis for IGFBP-6’s ability to inhibit IGF-II binding to
the IGF-IR (85). Although highly conserved, the N-terminal domain of IGFBP 1-5
contains a GCGCC motif which is not conserved in IGFBP-6. In IGFBP-6 the two
adjacent cysteine residues are missing, resulting in different disulphide linkages than die
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other binding proteins (86). This difference appears to be a contributing factor to the
unique preference of IGFBP-6 for IGF-II (86).
In addition to being a secreted protein, IGFBP-6 is also subject to proteolysis. Studies in
Madin-Darby canine kidney (MDCK) cells, an epithelial cell line derived from canine
kidney, suggest that IGFBP-6 proteolysis and the conformational change that
accompanies IGFBP-6 binding to IGF-II may prolong degradation rates (87). The balance
between proteolysis and glycosylation of IGFBP-6 helps maintain stability in IGF-II
binding and thus IGF-II function modulation. This equilibrium is due to the fact that nonglycosylated IGFBP-6 has a threefold increase in binding affinity for IGF-II, but
proteolysis also decreases the ability of IGFBP-6 to bind IGF-II significantly (88).
Therefore, the decrease in proteolysis of IGFBP-6 because of glycosylation leads to
higher IGF-II binding rates (88).
IGFBP-1, IGFBP-3 and IGFBP-5 human proteins have been shown to be phosphorylated
(89, 90); however, studies in CHO cells on human IGFBP-6 indicated that it is not
phosphorylated (91). Moreover, there is only one IGFBP-6 gene identified in humans,
while two IGFBP-6 genes have been identified in zebrafish (92).
The most commonly noted function of IGFBP-6 is the modulation of IGF-II activity. Like
other binding proteins, it can bind IGF-II in the circulation and protect it, as well as itself,
from proteolysis and thereby enhance IGF-II’s action by increasing its half-life. IGFBP-6
can bind IGF-II at the cell surface and enhance the action of this peptide by sequestering a
pool of IGF-II to the area and delivering to the IGF-IR (93). Alternatively, IGFBP-6 can
inhibit the action of IGF-II by binding to the peptide in the extracellular environment and
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preventing it from interacting with the IGF-IR; it is still not known how IGFBP-6 chooses
which function to perform. IGFBP-6 has been shown to have an effect on cell function
through its ability to sequester IGF peptides and prevent them from interacting with the
IGF-IR receptor in several different cell types. Moreover, IGFBP-6 expression is also
associated with non-proliferative states and inhibition of IGF-II-dependent tumor cell
growth, such as rhabdomyosarcoma, neuroblastoma, and colon cancer (94).
Neuroblastoma cells undergo a decrease both in cell proliferation and tumorigenic
potency as a result of exogenous IGFBP-6 expression, as IGFBP-6 reduces the ability of
IGF-II to stimulate a mitogenic response in the cells (95,96). In osteoblast cells, IGFBP-6
has also been shown to bind IGF-II and modulate its effects on cell growth by reducing
the bioavailability of IGF-II for its receptor in the bone microenvironment (97). In human
bronchial epithelial cells, IGFBP-6 over-expression induces a proliferative arrest, with no
evidence of apoptosis, suggesting an inhibition of IGF-II’s ability to induce mitosis (98).
Taken together, these examples show a strong role for IGFBP-6 in the modulation of IGF
peptide activity.

'

This ability to modulate IGF activity through binding the peptides and changing their
interactions with the IGF receptors were long thought to be the only function of the
binding proteins. However, recent evidence suggests that the IGF binding proteins,
including IGFBP-6, also act independently of the IGF peptides to affect cellular
functions. Binding proteins have been found to not only be secreted to the extracellular
environment where they interact with IGF peptide, but also localize to the intracellular
environment of the cell. Cytoplasmic and nuclear IGFBP-6 has been shown by Iosef et.al.
(99, 100), (Figure 4); and cytoplasmic IGFBP-6 has been imaged in Malassez epithelial
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cells and fibroblasts by Gotz et.al. (101). Due to the fact that the IGF peptides are rarely
found in the intracellular environment, this suggests that the binding proteins may have a
function independent of IGF-I and -II. Most commonly, the over-expression or ectopic
expression of any of the IGF binding proteins has led to the induction of apoptosis (96,
102-107). Previous studies in our laboratory linked IGFBP-6 to Ku proteins in regulating
cell fate (100). Moreover, the expression of IGFBP-6 is associated with non-proliferative
states such as cell differentiation (108). Also, IGFBP-6 over-expression in cells has either
a growth-promoting or a growth-inhibitory effect, depending on the cell type (109,110).
To date, no previous studies have been performed on IGFBP-6 and PMSCs. Moreover,
the conflicting data about IGFBP-6 in other cell lines raises many questions about how
this binding protein will function in PMSCs and how it affects the fate of these cells.
Therefore, in order to answer these questions and many more to come, we must first have
a general understanding about IGFBP-6’s role in PMSCs which is the focus of this study.
\
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Figure 4: Schematic o f IGF-dependent and -independent functions o f insulin-like
growth factor binding protein-6.

IGFBP-6 has three IGF dependent functions: a) to bind IGF-II and protect it from
degradation in the extracellular environment, thereby increasing its half-life, b) to bind
IGF-II and the extracellular matrix and help deliver it to the receptor, thereby enhancing
its function, and c) to bind IGF-II and prevent it from accessing the receptor, thereby
inhibiting its function. Recent studies have shown that IGFBP-6 is present in the
intracellular environment, as well as in the nucleus, suggesting the IGFBP-6 has IGF
independent functions, due to the fact that the IGF peptides are not found within the cell
(9 9 ,10<>, 101).
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these proteins indicates which stage the developing cell has passed. Before specification,
mesoderm cells express the mesoderm identifying protein Brachyury (T). Once the cells
become muscle precursors, after specification, the cells begin to express B-catenin,
Pax3/7, M oxl, Gli2 and Sixl (112, 113). The muscle precursor cells then undergo
commitment to become myoblast cells. Myoblasts express the myogenic regulatory
factors and the MEF2 proteins. Myoblasts are the last cell type in the differentiation
process that is able to divide. Once they undergo terminal differentiation the cells become
myocytes. Once myocytes are formed, the cells are no longer able to divide and start
expressing muscle specific proteins such as the myosin heavy and light chains. Myf-5 is
the first myogenic regulatory factor to be expressed in the developing embryo and
continues to be expressed through the development of muscle (114, 115). Shortly after
Myf-5 expression is detected, the expression of Myogenin is observed throughout the
myotome (116, 117), followed by MRF4 and MyoD respectively (118, 119). The MRFs
are able to trans-activate each other, and are able to positively regulate their own
expression (120,121,122,123).
The myogenic regulatory factors each serve distinct but overlapping functions in the
development of muscle. The use of knock-out experiments has helped elucidate the
function of the MRF proteins. Mice develop skeletal muscle normally when either Myf-5
or MyoD are lacking. The loss of myf-5 results in an up-regulation of MyoD, or
conversely the loss of MyoD results in an up-regulation of Myf-5 (124, 125). However,
when both are missing, myoblasts do not form, suggesting that Myf-5 and MyoD have
overlapping roles and can compensate for the loss of the other (126). The loss of Myf-5
and MyoD together is perinatal lethal due to respiratory failure from a total lack of
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muscles in the trunk. Myogenin is also necessary for survival. When it is lacking in mice,
the mutations are also perinatal lethal, and the mice die shortly after birth due to severe
muscle deficiency and the resulting respiratory failure (127).
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Figure 5: Overview o f muscle differentiation.

Myogenesis can be divided into three distinct stages. After completing each of these
stages the differentiating cell begins to express specific proteins which can be used to
distinguish what point in the differentiation process the cells are at. Quiescent skeletal
muscle satellite cell can become activated and start to proliferate into skeletal myoblasts
that express the paired-box transcriptions factors Pax7 and Pax3, as well as the myogenic
regulatory factors Myf5 and MyoD. Once committed to differentiation, myoblasts stop
cycling and lose expression of Pax7, Pax3, and Myf5. Differentiating Myogenin positive
myocytes will then align and fuse to form multinucleated myofibers. The MRFs are
considered to be the master regulatory proteins of muscle development. Once the MRFs
(myogenic regulatory factors) are expressed, cells are destined to become muscle cells
and can no longer differentiate into other cells types.
(http://www.sciencedirect.com/science/article/pii/S0955067407001342)
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1.4.2

Insulin-like Growth Factors and M yogenesis

The insulin-like growth factor super-family has been shown to have a role in muscle
development. One clear demonstration of the importance of IGFs and the type I IGF
receptor for muscle development is loss-of-function studies that have been performed. In
IGF-I or IGF-IR knock-out mice the embryos die prematurely. The pups are unable to
survive because functional muscle is completely lacking and thus they are unable to
breathe (128, 129). When there is an increase in the amount of IGF-I present during
development (as a result of transgenic over-expression) muscle and bone were increased
by 30% with a 50% increase in IGF-I levels (130). Together, these two types of studies
point to an important role for IGF-I and its receptor in muscle development. The IGF
peptides act to stimulate of both proliferation and terminal differentiation in a temporally
separated manner. When L6E9 cells (a myoblast cell line used to study late myogenesis)
are stimulated with IGF-I there is an initial proliferative response. During this time of
rapid cell division the myogenic regulatory factors are inhibited. Approximately 30 hours
later there is a stimulation of Myogenin expression and activity and the mitogenic factors
are suppressed (131). These studies suggest an important role for IGF peptides and the
type I receptor in the stimulation and regulation o f myogenesis. However, the
downstream factors involved in IGF stimulated differentiation still remain elusive.
Although the above factors have been shown to affect Myogenin expression and
myogenesis in cell culture experiments, it is not known whether the same factors link
IGF, Myogenin and myogenesis in the developing embryo in a similar manner. In
addition to the well-studied effects of IGF-I and II on Myogenin expression, IGF-II has
been shown to play a role in the regulation of MyoD function. When MyoD is expressed
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in C3H 10T1/2 mouse embryonic fibroblast cells, there is an induction of IGF-II
expression and subsequent activation of the IGF-IR and its downstream target Akt (132).
When activation of either IGF-II target is inhibited, myogenesis does not occur (133). In
fact, the IGF-II is required to allow continued recruitment of MyoD-associated proteins at
the Myogenin promoter (134).
1.4.3

Insulin-like Growth Factor Binding Protein-6 and M yogenesis

IGFBP-6 has been shown to be expressed during embryonic development in many
different tissues including the ossifying bones of the cranium, myoblasts and the motor
neurons of the spinal cord (134). Previous studies in our laboratory have shown that
rhabdomyosarcoma cells (RD cells) treated with mutant IGFBP-6 (non-nuclear)
underwent terminal differentiation and that the expression of muscle specific myosin
heavy chain was achieved in 0.05% of the cells compared to 0% of the untransfected RD
cells or wild-type IGFBP-6 expressing cells. This percentage is significant due to the fact
that untransfected RD cells, RD cells transfected with the empty vector or RD cells
\

expressing the wildtype IGFBP-6 never underwent myogenesis.
In this study, we propose to culture skeletal muscle from placental mesenchymal stem
cells and then test the effects of IGFBP-6 early before these cells commit to the muscle
lineage (Figure 6).
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Figure 6: Proposed model.

Growing muscle cells form placental mesenchymal stem cells and testing the effects of
early insulin-like growth factor binding protein-6 on myogenesis before the cells commit
to the muscle lineage.
(http://www.sciencedirect.com/science/article/pii/S0955067407001342)
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2.0 HYPOTHESIS

IGFBP-6 inhibits the maintenance of pluripotency of placental mesenchymal stem cells
and promotes their differentiation into muscle via intracellular or extracellular routes
through IGF-dependent or -independent mechanism.

2.1 OBJECTIVES

(1) To confirm that PMSCs have the ability to differentiate into muscle cells.
(2) To evaluate the intracellular and extracellular effects of IGFBP-6 on differentiation of
developing muscle cells.

2.2 RATIONALE

Increasing IGFBP-6 in the placental mesenchymal stem cells microenvironment was
expected to deplete the system of IGF-II and therefore prevent it from interacting with the
IGF receptor and negatively affect differentiation. Conversely, silencing of IGFBP-6
expression was expected to increase the differentiation of these cells, as a result of a
greater availability of IGF-II (93, 97). In addition, IGFBP-6 is known to be present in the
cytoplasm as well as in the nuclei (99, 100) suggesting that IGFBP-6 may have IGF-II
independent function.
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3.0 M ATERIALS and METHODS
3.1 Reagents
3.1.1 Cell Culture Reagents

Dulbecco's Modified Eagle Medium Nutrient Mixture F-12 (DMEM/F12), Dulbecco’s
Phosphate Buffered Saline (DPBS), ES-Quality Fetal Bovine Serum (FBS), lOx 0.5%
Trypsin-EDTA and FGF-2 were purchased from Gibco-Invitrogen (Burlington, ON,
CAN). Tissue culture flasks, 6 well plates, and 24 well plates were purchased from BD
Falcon (Mississauga, ON, CAN), and filters were purchased from Nalgene (Rochester,
NY, USA).
3.1.2 M uscle Differentiation Reagents

Skeletal muscle growth media (fetal calf serum 0.05 ml/ml, bovine 50 pg/ml, epidermal
growth factor 10 ng/ml, basic fibroblast growth factor 1 ng/ml, insulin 10pg/ml, and
dexamethasone 0.4 pg/ml); and skeletal muscle differentiation media which is serum-free
medium containing only lOpg/ml insulin, were both purchased ' from Promocell
(Heidelberg, Germany).
3.1.3 Insulin-Like Growth Factor Binding Protein-6

Recombinant Human IGFBP-6 was purchased from PROSPEC (Rehovot, Israel). The
recombinant protein was resuspended in sterile MQ-H2 O and stored at -20°C. For use in
the experiments, the vial was thawed and added to DMEM/F12 at a concentration of 750
ng/well.
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3.2 Placental M esenchymal Stem Cell Culture in M uscle Differentiation Conditions

Cells previously obtained from preterm placental tissue (13-weeks) were cultured and
maintained using DMEM/F12 media supplemented with 10% ES-FBS serum and FGF-2
(25 ng/mL) (GIBCO/Invitrogen) in tissue culture flasks (BD Falcon). These cells have
been characterized extensively and compared to several cell lines obtained from late first
trimester placentae, and they are similar to others (36, 37, 43, 44). This cell line (the
chorionic villi derived MSCs) is chosen as a representative first trimester PMSC to be
studied. When cell cultures reached 90-100% confluency, the cells were passaged 1:2
approximately once per week using 0.05% Trypsin (GIBCO/Invitrogen) for 5-10 min at
37°C for dissociating cells and the medium was changed as needed approximately every
two days. For treating cells under various conditions, 70-80% confluent cells in 6-well
plates (BD Falcon) were grown in the presence of the muscle growth media (Promocell)
for 24 hours before changing to the skeletal muscle differentiation media for muscle
differentiation conditions. Finally, for IGFBP-6 treatment, cells were incubated with 0.75
pg/well of recombinant human IGFBP-6 protein (Prospec Protein Specialists) or silenced
with IGFBP-6 siRNA (Santa Cruz, CA, USA). The cells were grown in a standard tissue
culture incubator at 37°C in 5% CO2 .
3.2.1 Placental Mesenchymal Stem Cell Freezing and Thawing

1 mL of freezing media (30% FBS and 10% DMSO in DMEM/F12 media) was used to
resuspend the pelleted PMSCs and the cells were frozen at -20°C for 30 minutes before
transferring the cells to -80°C. Vials were thawed at room temperature when needed. The
cells were resuspended in normal culture media (25 ng/ml FGF-2 and 10% ES-FBS in
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DMEM/F12 media) for seeding after they were pelleted by centrifugation at 1000 rpm for
5 minutes.
3.3 IGFBP-6 Protein Transport System (Chariot™ )

The Chariot™system was purchased from Active Motif (Carlsbad, CA, USA). It is a
delivery reagent that quickly and efficiently transports biologically active proteins,
peptides and antibodies directly inside the cells. We used Chariot
intracellular recombinant IGFBP-6 protein into PMSCs. Chariot

to deliver the

was prepared as stated

by the company protocol. Following 24 hour of incubation in serum free medium, cells
were washed with DPBS (lx) and a mixture of Chariot ™ and IGFBP-6 was added to
cells in 6-well plates for 1 hour in 400 pL of serum free media (DMEM/F12) in a
standard tissue culture incubator at 37°C in 5% CO2 . Afterwards, another 400 |iL of
DMEM/F12 media was added in each well for an additional 2 hours in a tissue culture
incubator at 37°C in 5% CO2 (Figure 7). Then the Chariot™ complex was washed from
the cells with DPBS (lx) and the muscle growth media was added for non-differentiated
conditions and muscle differentiation media for the differentiated conditions. Cells were
T\yf
lysed after 0, 12, 24, 48, 72 hours and 7 days following removal of the Chariot
complex.
P-galactosidase staining was used in order to test efficiency of the Chariot

delivery

system. When p-galactosidase hydrolyses X-gal, it produces a blue color that can be
visualized under a bright field microscope. The P-galactosidase was prepared as stated in
the Chariot

manual (Active Motif) and then added to the cells grown in a 6-well plate

for 2 hours in a standard tissue culture incubator at 37°C in 5% CO2 . Finally, the cells
were studied under a microscope (Figure 8).
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Figure 7: Diagram o f the Chariot™ Process.

A mixture of Chariot™ and IGFBP-6 was added to the cells after washing with DPBS
(lx) in 6-well plates for 1 hour in 400 pL of serum free media (DMEM/F12) in a standard
tissue culture incubator at 37°C in 5% CO2 ; cells were serum starved for 24 hours prior to
treatment. After that, another 400 pL of DMEM/F12 media was added in each well for an
additional 2 hours in a tissue culture incubator at 37°C in 5% CO2 .
(www.activemotif.com)
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Figure 8: Chariot™ system efficiency.

Chariot™ transport system introduced indicator protein inside the PMSCs using X-gal
detection under bright field microscopy by ß-galactosidase transfected into placental
mesenchymal stem cells grown in muscle growth media; (-90% of cells were positively
stained).
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3.4 Down-regulation of IGFBP-6 Expression by siRNA
In order to silence the endogenous IGFBP-6, siRNA against IGFBP-6 (Santa Cruz, CA,
USA) was used to transfect PMSCs grown in a 24-well plate. The siRNA has a pool of 3
target-specific 20-25 nt siRNAs. 8 pL of Lipofectamine (Invitrogen) with either 8 pL of
scrambled siRNA (control) or siRNA-IGFBP-6 was added to 100 pL of DMEM/F12
media (transfection solution) for 40 minutes at room temperature; the concentration of
siRNA in the solution was 80 nM. This solution was then added to the 80% confluent
cells cultured in 6-well plates after washing with DPBS (2x) and incubated for 7 hours at
37°C; 1 mL of muscle growth media or skeletal muscle differentiation media (Promocell)
was added to the cells depending on the condition after the removal of the transfection
solution. The cells were then lysed after 24, 48, 72 hours, and 7 days.
3.5 Cell Lysate Preparation
After specific treatments and incubation time at 37°C, cells were washed with ice-cold
DPBS while on ice. 200 pL of (lx) cell lysis buffer purchased (Cell Signaling
Technologies.Danvers, MA) mixed with protease inhibitor (1:100) as stated in the
company protocol, was added to the cells. Cells were detached using a cell scraper; the
lysate was then sonicated for 15 seconds, and then placed on ice for 10 minutes. Finally,
the samples were centrifuged for 15 min at 14,000 rpm at 4°C, and the supernatant was
collected and stored at -80°C.
3.6 Protein Assay
The Bio-Rad protein assay was purchased from Bio-Rad (Mississauga, Ontario) and used
to quantify the protein concentration of cell lysates and Bovine Serum Albumin (BSA)
standards (concentrations of 750, 500, 250, 125, 25, 0 pg/mL) purchased from Thermo
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Fisher Scientific (Rockford, IL); samples were either diluted to 1:10 or 1:5. Duplicate 10
pL aliquots of each sample and standard were pipetted into a 96-well plate (Thermo
LabSystems, Milford MA, USA) containing 200 pL of diluted (1:4) Bio-Rad protein
assay reagent in dHLO. The plate was then placed in Thermo LabSystems Multiskan
Ascent Plate Reader (Thermo LabSystems) to read protein concentration at absorbance of
595 nm. Standard curve and protein concentrations were analyzed using Multiskan
Ascent analysis software (Thermo LabSystems).
3.7 Immunocytochemistry Procedure
Placental mesenchymal stem cells were grown in 6-well plates on glass slips and
incubated with primary antibodies at 4°C overnight after blocking in 2% BSA for an
hour. The primary antibodies (Table 1) were then washed away using PBS (3x for 10
min), cells were then incubated with the secondary antibody for an hour at room
temperature while covered with aluminium foil. The secondary antibody (Table 3) was
washed using PBS (3x for 10 min). Cells were rinsed with water for 5 minutes and the
nuclear stain (Hoechst dye) was added for 7 minutes, and then rinsed out using water for
10 minutes. Finally, the slides were mounted with 70% glycerol: 30% PBS cover slipped
and then stored over night at 4°C. The images were taken using either a Leica inverted
microscope or an Olympus fluoview confocal microscope.
3.8 Immunoblotting Procedure
3.8.1 Sample Preparation
20pg of each protein sample was added to 6x SDS gel loading buffer (1% Pmercaptoethanol, 1% SDS, 30% glycerol, 0.0012% bromophenol blue, Tris HC1 0.28 M,
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pH 6.8). Samples were boiled for 5 minutes at 95° and then placed on ice for 3 minutes.
Finally, the samples were briefly centrifuged at 3000 rpm for 20 seconds before loading.
3.8.2 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis and Protein
Transfer
Protein samples were resolved by molecular weight using 10% sodium dodecyl sulfate
(SDS) polyacrylamide gel electrophoresis (PAGE) gels made of 0.375 M Tris HC1 pH
8.8, 0.125 M Tris HC1 pH 6.8, 30% acrylamide/bis solution (29:1), 10% ammonium
persulfate, and 0.01% TEMED . Protein samples were loaded next to one well containing
12 pL of BenchMark Prestained Standard mixed with 2.5 pL of MagicMark XP
(Invitrogen, Mississauga, ON). Samples were separated at U=80 V until the dye front
passed through the stacking gel, and the voltage was raised to 120 V for the remainder of
the electrophoresis. Gels were transferred onto poly-vinyl-dene-fluoride (PVDF)
membranes (Millipore) in transfer buffer for 2 hours at 700 constant mA.
3.8.3 Antibody Probing
After transfer, the membranes were blocked with 5% non-fat-dry milk, gently shaking for
1 hour at room temperature in Tris-HCl buffer saline pH 8.0 with 0.1% Tween-20 (TBST). Blots were then washed with lx TBS+ 0.1 % Tween 20 (3x for 5 min) followed by
incubation at 4°C overnight on the shaker with specific primary antibodies in 5% BSA or
5% non-fat-dry milk in TBS-T following the manufacturer’s protocol (See Table 1). Then
membranes were washed with lx TBS-T (3x for 10 min), blots were then incubated for an
hour at room temperature with the corresponding secondary HRP antibody (See Table 2).
The unbound antibody was washed with TBS-T (3x forlO min).

Table 1. Prim ary antibodies for western blotting and/or immunocytochemistry.
Name

Origin

Dilution and Diluent

Company and
Catalogue Number

1:1000 for western blots in 5%
IGFBP-6

Rabbit

milk, TBS-T

Santa Cruz,
Cat# sc- 13094

polyclonal
1:50 for
immunocytochemistry
1:300 for western blots in 5%
Pax3/7

Rabbit

milk, TBS-T

Santa Cruz,
Cat# sc- 25409

polyclonal
1:50 for
immunocytochemistry
1:300 for western blots in 5%
BSA, TBS-T
Oct3/4

Santa Cruz,
Cat# sc- 8628

Goat Polyclonal
1:100 for
immunocytochemistry

Pan Actin

Mouse
monoclonal

1: 2000 for western blots in
5%

milk, TBS-T

Neo markers,
Cat# MS-1295-P
Santa Cruz,

MyoD

Mouse

1:100 for

monoclonal

immunocytochemistry

Cat# sc- 32758

Santa Cruz,
Myogenin

Mouse

1:100 for

monoclonal

immunocytochemistry

Cat# sc- 12732

44

Table 2. Secondary antibodies for western blots.
Name

Origin

Dilution

Company and Catalogue Number

Anti-goat IgG HRP

Donkey

1:15,000

Santa Cruz, Cat# sc-2020

Anti-rabbit IgG

Goat

1:10,000

Bio-Rad, Cat# 170-6515

Goat

1:10,000

Bio-Rad, Cat# 170-6516

HRP
Anti-mouse IgG
HRP

Table 3. Secondary antibodies for immunocytochemistry.
Name

Origin

Dilution

Company and Catalogue Number

Alexa Fluor® 568

Goat

1:50

Invitrogen, Cat# 835724

Donkey

1:50

Invitrogen, Cat# A-11055

Goat

1:50

Invitrogen, Cat# A-11031

goat anti-rabbit IgG
Alexa Fluor® 488
donkey anti-goat
IgG
Alexa Fluor® 568
goat anti-mouse
IgG
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3.8.4 Chemiluminescence, Imaging, and Densitometry
Resolved protein bands were detected using chemiluminescence (ECL) by incubating the
membranes for 2-4 minutes according to the manufacturer’s instruction (Amersham).
Images were taken using the VersaDoc Imager (Bio-Rad). Densitometry was performed
using Image lab software (Bio-Rad). The band intensities were normalized to loading
control (pan-Actin).
3.8.5 Stripping Western Blot Membranes
After detection, membranes were rinsed in distilled water and then were stripped using
NaOH (0.5M solution) for 15 min on a platform shaker at room temperature. The
membranes were washed with distilled H2O for 10 minutes on the shaker. Membranes
were re-blocked in TBS-T containing 5% non-fat dried milk in preparation for the next
immunoblotting experiment.
3.9 Quantification of the IGFBP-6 production by Enzyme-Linked Immunosorbent
Assay (ELISA)
Human IGFBP-6 ELISA kit (RayBio®) was used to measure the amount of IGFBP-6
secreted into the media of different treatment conditions. The media was collected at 0,
12, 24, 48, 72 hours and 7 days post-treatment. This is an assay that employs an antibody
specific for human IGFBP-6 coated on a 96-well plate. Standards and samples were
loaded into the wells and IGFBP-6 present in the sample was bound to the wells by the
immobilized antibody. The wells were washed and biotinylated anti-human IGFBP-6
antibody was added. After washing away unbound biotinylated antibody, HRPconjugated streptavidin was added. After washing again, a TMB substrate solution was
added and a blue color developed in proportion to the amount of IGFBP-6 bound. The
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Stop Solution changes the color from blue to yellow, and the intensity of the color was
measured at 450 nm (RayBio®). Results were analyzed using Multiskan Ascent analysis
software (Thermo LabSystems).
3.10 Statistical Analysis
For data analysis GraphPad Prism 5 analysis software (La Jolla, CA) was used. Three
independent experiments were performed; within each experiment, some replicates were
performed (depending on the amount of cell lysate available). Comparisons between
groups were analyzed by either One-way or Two-way ANOVA followed by a t-test at
each time point and significant difference was considered when p<0.05. Graphic
representation values are presented as mean ± (SEM shown as variance bars).
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4.0 RESULTS
4.1 Placental Mesenchymal Stem Cell Differentiation into Skeletal Muscle
Placental mesenchymal stem cells (PMSCs) have the ability to differentiate into a diverse
range of tissues, including muscle. Therefore, PMSCs cultured in the laboratory under
specific conditions can differentiate into skeletal muscle cells (3).
To determine if PMSCs have the ability to differentiate into skeletal muscle cells, cells
were grown in 6-well plates on glass slips in muscle differentiation media (serum free
with lOpg/ml insulin), and stained for the early muscle marker Pax3/7 at day 3 post
differentiation, and for late muscle markers Myogenin and MyoD at 14 days post
differentiation. Fluorescent microscopy shows that placental mesenchymal stem cells do
differentiate into muscle committed cells as they express Pax3/7 (Figure 9A) and show
multi-nucleation (Figure 9B) at day 3. Moreover, at the protein level, Pax3/7 levels
increased over time until they reached a two-fold increase at 72 hours (Figure 9C).
PMSCs also express Myogenin (Figure 9D) and MyoD (Figure 9E) at day 14. Also at day
14, with phase contrast microscopy, PMSCs show the formation of multi-nucleated fibers
(Figure 10).
The expression of OCT4, 3days post-differentiation under muscle differentiation
conditions (Figure 11A), had no significant change at the protein level over time (Figure
11B), which suggests that placental mesenchymal stem cell differentiation into muscle
has no effect on OCT4 expression. On the other hand, IGFBP-6 expression was also
observed in these cells (Figure 11C) with an increase in protein level over time (1-fold) at
day 3 (Figure 1ID), confirming that developing muscle cells express IGFBP-6.

Figure 9: Placental mesenchymal stem cells have the ability to differentiate into
muscle.
Using Olympus fluoview confocal microscope, PMSCS grown in muscle differentiation
media (serum free with lOpg/ml insulin) are immunoreactive for, (A) early muscle
marker Pax3/7 (red-Alexa 568, >.-568 nm) (B) showed multi-nucleation process [40X]
with positive staining for Pax3/7 and (C) increased protein levels of Pax3/7 at 72 hours
(2-folds) at days 3 post-differentiation. At 2 weeks post-differentiation, PMSCs are
immunoreactive for (D) Myogenin (cytoplasmic localization), and (E) MyoD (intra
nuclear localization). Lower row shows magnification of the boxes in the upper row.
Nuclei were stained with Hoechst dye (blue, >=340 nm). The arrows show the multinucleation formation.
For western blot, the top panel shows a representative western blot of three independent
experiments and the lower panel shows the quantification and statistical analysis of
replicate experiments. Error bars represent the standard error of the mean (SEM). (One
way ANOVA followed by t-test, ***=p<0.001).
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Figure 10: Placental mesenchymal stem cells show muscle-like morphology at 14days post-differentiation.
(A) PMSCs grown in normal culture media (25 ng/ml FGF-2 and 10% ES-FBS in
DMEM/F12 media) did not show muscle formation compared with (B) PMSCs grown in
muscle differentiation media (serum free with 10gg/ml insulin) showed skeletal muscle
morphology at day 14. (C) Multi-nucleated skeletal muscle cells were derived from
placental MSCs grown under muscle differentiation conditions (contrast phase imaging).
Arrows show the multi-nucleated process.
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(B)

(A)

Control

Skeletal muscle differentiation

Figure 11: Placental mesenchymal stem cells grown in muscle differentiation media
show increasing levels of IGFBP-6 by time with no change in OCT4.
Using Olympus fluoview confocal microscope, PMSCS grown in muscle differentiation
media (serum free with lOpg/ml insulin) are immunoreactive for, (A) stem cell marker
OCT4 (green-Alexa 488, 1=488 nm), with (B) no significant changes in OCT4 protein
levels using Western blots. (C) IGFBP-6 (red-Alexa 568, 1-568 nm) was observed (D)
with a one-fold increase in the protein level at day 3 in PMSCs under muscle
differentiation conditions. By western blot, OCT4 and IGFBP-6 levels were quantified
and normalized to [3-Actin and then normalized to 24 hours using Versadoc software
(Bio-Rad). The top panel shows a representative western blot of three independent
experiments and the lower panel shows the quantification and statistical analysis of
replicate experiments. Error bars represent the standard error of the mean (SEM). (One
way ANOVA followed by t-test, *= P<0.05). For confocal images, Nuclei were stained
with Hoechst dye (blue, X=340 nm) for confocal images.
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4.2 IGFBP-6 Intracellular Actions on Developing Muscle Cells
To determine the effects of increased intracellular IGFBP-6 on placental mesenchymal
stem cells grown in muscle growth media, the Chariot™ system was first tested using a
staining kit in order to evaluate the system efficiency (Figure 8). Positive staining in 90%
of cells indicates that the system was efficient in introduction of the control protein into
the PMSCs. It is expected that the system would introduce IGFBP-6 with similar
efficiency into PMSCs.
Under non-differentiation conditions, IGFBP-6 was elevated in PMSCs when IGFBP-6
was introduced using the Chariot™ system as shown with the significant increase at 12
hours compared to the Chariot™ control (Chariot system without IGFBP-6) and this
over-expression was transient as seen with the reduction in IGFBP-6 at 24 hours
compared to the Chariot™ (+)IGFBP-6 at 12 hours (Figure 12A). At day 7, there was a
significant increase in both IGFBP-6 (Figure 12A) and Pax3/7 (Figure 12B), which
indicates that there may be an association between IGFBP-6 and Pax3/7 expression that
could have been set by the initial elevation of IGFBP-6 by the Chariot™ system. In
contrast, there was no significant changes in OCT4 levels at any of the time points
(Figure 12C), suggesting that OCT4 expression was not affected by the increase in
IGFBP-6 under non-differentiation conditions.
Also, using ELISA, there was a significant increase in IGFBP-6 levels secreted into the
media at both 24 and 48 hours with the intracellular increase of IGFBP-6 using Chariot™
with a significant reduction at day 7 (Figure 13),compared to both PMSCs alone and
PMSCs with only Chariot™, indicating that adding intracellular IGFBP-6 increased
IGFBP-6 secretion; and as the levels of IGFBP-6 increased, as seen using western blots,
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at day 7 (Figure 12A) the amount secreted to the media is reduced at the same time point
(Figure 13).
Under differentiation conditions, there was no significant change in IGFBP-6 (Figure
14A), OCT4 (Figure 14B), or Pax3/7 (Figure 14C) levels at each time point indicating
that the changes caused by an increase in intracellular IGFBP-6 was more prominent
under non-differentiation conditions before the PMSCs commit to the muscle lineage.
In contrast, by ELISA, there was a significant increase in the levels of IGFBP-6 secreted
into the media with the intracellular increase (Figure 15), thus, increasing intracellular
IGFBP-6 increased the amount of IGFBP-6 secreted into the media.
To evaluate the effects of IGFBP-6 silencing using siRNA on PMSCs grown in either
muscle growth media or muscle differentiation media, a time course experiment was
conducted to determine IGFBP-6, OCT4, and Pax3/7 levels 24, 48, 72 hours and 7 days
after silencing.
Under non-differentiation conditions, there was a significant reduction in IGFBP-6 levels
at 24 hours with IGFBP-6 silencing compared to the scrambled siRNA (used as control)
(Figure 16A). This reduction was temporary and the IGFBP-6 levels returned to control
levels by day 7 (Figure 16B). There was also a significant decrease in OCT4 levels at
each time point with IGFBP-6 silencing (Figure 16C), which suggests that the IGFBP-6
silencing had an effect on OCT4. In contrast, there was a significant increase in Pax3/7
level at 24 hours with IGFBP-6 silencing (Figure 16D) that remained constant thereafter,
suggesting that with IGFBP-6 silencing under non-differentiation conditions, PMSCs
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responded by compensating for IGFBP-6 silencing by promoting and enhancing the
differentiation process.
Under differentiation conditions, IGFBP-6 levels were restored at day 7 after IGFBP-6
silencing indicating that the siRNA effect was short term (Figure 17A). Interestingly, the
cells that were treated by silencing IGFBP-6 had more significant increase in IGFBP-6
levels compared to the cells treated with the scrambled siRNA at day 7 (Figure 17A).
OCT4 levels significantly decreased over time with IGFBP-6 silencing (Figure 17B).
There was a significant increase in Pax3/7 levels at each time point compared to the
scrambled siRNA but overall it seems that both treatments are going down with time, but
the cells with the IGFBP-6 silencing had Pax3/7 decreased less (Figure 17C). Therefore,
IGFBP-6 silencing may allow PMSCs to differentiate faster than the control cells.
IGFBP-6 levels in the media as determined by ELISA showed that there was a significant
decrease at each time point in IGFBP-6 levels secreted into the media with IGFBP-6
siRNA compared to the scrambled siRNA under both non-differentiation (Figure 18) and
differentiation conditions (Figure 19), indicating that IGFBP-6 silencing using siRNA
also decreased the amount of IGFBP-6 secreted to the media.

Figure 12: Time course experiment for increased intracellular IGFBP-6 by
Chariot™ in PMSCs under non-differentiation conditions.
IGFBP-6, OCT4, and Pax3/7 levels as determined by Western blotting over time in
PMSCs grown in muscle growth media after using the Chariot™ system to increase
intracellular IGFBP-6 (0.75 p.g/ well of recombinant human IGFBP-6 protein); the top
panel shows a representative western blot of four independent experiments and the lower
panel shows quantitative analysis of the densitometry. (A) IGFBP-6 levels significantly
increase at both 12 hours and 7 days compared to Chariot™ control; at 24 hours there is
significant reduction in IGFBP-6 levels with intracellular IGFBP-6. (B) Intracellular
IGFBP-6 increases Pax3/7 levels significantly at day7. (C) There is no significant effect
on OCT4 levels at any of the time points in non-differentiation conditions compared to
Chariot™ control (-) IGFBP-6. Protein levels were quantified and normalized to P-Actin
using Versadoc software (Bio-Rad). Error bars represent the standard error of the mean
(SEM). (*) indicates comparison between the different conditions, while (#) indicates
comparison within the same treatment over time. (Two-way ANOVA followed by a t-test,
*= P<0.05, ***=p<0.001).
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Figure 13: ELISA for the time course experiment for increased intracellular IGFBP6 by Chariot™ in PMSCs under non-differentiation conditions.
IGFBP-6 levels secreted to the media increased over time after using Chariot™ to
increase intracellular IGFBP-6 (0.75 jj.g/ well of recombinant human IGFBP-6 protein);
significant increase at 24 hours and 48 hours in non-differentiation conditions. At day 7,
there was a significant decrease in intracellular IGFBP-6 compared to the controls
(control^ PMSCs in muscle growth media alone, Chariot™ control^ Chariot complex
only); Chariot™ was applied only once at the beginning of the experiment. Error bars
represent the standard error of the mean (SEM) as calculated from triplicate experiments.
(Two-way ANOVA followed by a t-test, P<0.001, n=3).
ELISA sensitivity: Highest amount detectable 60,000 pg/ml; lowest amount detectable
82.3 pg/ml. Standard curve R2 = 0.99
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Figure 14: Time course experiment for increased intracellular IGFBP-6 by
Chariot™ in PMSCs under differentiation conditions.
Images show Western blot analysis of lysates from PMSCs grown in muscle
differentiation media with Chariot™ to increase the intracellular IGFBP-6 (0.75 pg/well
of recombinant human IGFBP-6 protein); the top panel shows a representative western
blot of four independent experiments and the lower panel shows quantification and
statistical analysis. Intracellular increase of IGFBP-6 by Chariot™ had no significant
effects on (A) IGFBP-6 levels, (B) OCT4 levels, or (C) Pax3/7 levels in differentiation
conditions compared to Chariot™ control.
By western blot, protein levels were quantified and normalized to (3-Actin using Versadoc
software (Bio-Rad) and levels presented as means and standard error of the mean (SEM).
(Two-way ANOVA followed by a t-test, P<0.05, n=4).
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Figure 15: ELISA for the time course experiment for increased intracellular IGFBP6 by Chariot™ in PMSCs under differentiation conditions.
IGFBP-6 levels secreted into the media increased over time after using Chariot™ to
increase the intracellular IGFBP-6 (0.75 pg/ well of recombinant human IGFBP-6
•I *1 1

protein) compared the control (PMSCs alone) and to the Chariot

•m i jr

control (Chariot

complex only) in differentiation conditions; Chariot™ was applied only once at the
beginning of the experiment. IGFBP-6 levels are presented as means and standard error of
the mean (SEM) as calculated from triplicate experiments. (Two-way ANOVA followed
by a t-test, *= P<0.05, ***=P<0.001, n=3).
ELISA sensitivity: Highest amount detectable was 60,000 pg/ml; lowest amount
detectable was 82.3 pg/ml. Standard curve R2 = 0.98
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Figure 16: Time course experiment for silencing IGFBP-6 expression in PMSCs
under non-differentiation conditions.
Images show Western blot analysis of lysates from cells treated with siRNAs against
IGFBP-6, or scramble siRNA as a control, over time in PMSCs grown in muscle growth
media; siRNA treatment was applied only once at the beginning of the experiment. The
top panel shows a representative western blot of three independent experiments and the
lower panel shows a diagram of the statistical analysis.
(A) After 24 hours, Silencing IGFBP-6 significantly decreases IGFBP-6 levels by 50%
compared to the scrambled siRNA. (One-way ANOVA followed by a t-test,
***=P<0.001). (B) Silencing IGFBP-6 is transient and IGFBP-6 is significantly
increased at day 7. (C) Significant decrease in OCT4 levels at each time point with
IGFBP-6 silencing. (D) Silencing IGFBP-6 significantly increase Pax3/7 levels at 24
hours in non-differentiation conditions.
IGFBP-6 levels were quantified and normalized to P-Actin. The IGFBP-6 levels are
presented as mean and standard errors of the mean (SEM) as calculated from triplicate
experiments. (*) indicates comparison between the different conditions, while (#)
indicates comparison within the same treatment over time. (Two-way ANOVA followed
by a t-test, *= P<0.05, **-P<0.01).
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Figure 17: Time course experiment for silencing of IGFBP-6 expression in PMSCs
under differentiation conditions.
Images show Western blot analysis of lysates from cells treated with siRNA to IGFBP-6,
or scramble siRNA as a control over time in PMSCs grown in muscle differentiation
media; siRNA treatment was applied only once at the beginning of the experiment. The
top panel shows a representative western blot of three independent experiments and the
lower panel shows a diagram of the statistical analysis. (A) Silencing IGFBP-6 with
siRNAs significantly decreased IGFBP-6 levels by 40% at 24 hours compared to controls
(scrambled siRNA) (One-way ANOVA followed by a t-test, **=P<0.01). (B) Silencing
IGFBP-6 was transient and IGFBP-6 levels were significantly increased at day 7. (C)
Concurrent with reduction in IGFBP-6, there was a significant decrease in OCT4 levels,
(D) with a significant increase in Pax3/7 levels at each time point in differentiation
conditions. By western blot, IGFBP-6 levels were quantified and normalized to P-actin.
IGFBP-6 levels are presented as means and standard error of the mean (SEM). (Two-way
ANOVA followed by t-test, *=P<0.01***=P<0.001).
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Figure 18: ELISA for the time course experiment for silencing IGFBP-6 expression
in PMSCs under non-differentiation conditions.
IGFBP-6 secreted into the media decreased significantly at each time point after treatment
with siRNA against IGFBP-6 compared to the scrambled siRNA. siRNA treatment was
applied only once at the beginning of the experiment. IGFBP-6 levels axe presented as
mean and standard error of the mean (SEM) as calculated from triplicate experiments.
(Two-way ANOVA followed by a t-test, PO.OOl, n=3).
ELISA sensitivity: Highest amount detectable 60,000 pg/ml; lowest amount detectable
82.3 pg/ml. Standard curve R2 = 0.99

Levels of secreted IGFBP-6 (pg/ml)

81

IG FBP-6

si (C o n tro l)
si (IG F B P -6)

1500i

1000-

***
* * *

* * *

l

1

48 hours

72 hours

lm_ ■ ■ I
* *

24 hours

7 days

Tim e cou rse for non -d ifferen tiation conditions

F ig u r e 19: T im e c o u r s e o f c h a n g e s in I G F B P -6 s e c r e te d in t o t h e m e d ia fo llo w in g
s ile n c in g o f I G F B P -6 e x p r e s s io n in P M S C s u n d e r d if fe r e n t ia tio n c o n d itio n s .

IGFBP-6 levels secreted into the media decreased significantly after treatment with
siRNA against IGFBP-6 compared to controls (scrambled siRNA); siRNA treatment was
applied only once at the beginning of the experiment. IGFBP-6 levels are presented as
means and standard error of the mean (SEM) as calculated from triplicate experiments.
(Two-way ANOVA followed by a t-test, P<0.001, n=3).
ELISA sensitivity: Highest amount detectable was 60,000 pg/ml; lowest amount
detectable was 82.3 pg/ml. Standard curve R2 = 0.98
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4.3 Extracellular Actions of IGFBP-6 on Developing Muscle Cells
IGFBP-6 is present in the mesenchymal stem cell microenvironment, and extracellular
IGFBP-6 is expected to regulate the bioavailability of IGFs (especially IGF-II). Since
IGF-II has been recently identified as one of the main regulators of the embryonic stem
cell proliferation, the excess of IGFBP-6 is expected to deplete the system of IGF-II, and
therefore, down-regulate stem cell proliferation (95, 96, 97, 98,135).
To test the effects of extracellular IGFB-6 on developing muscle cells, placental
mesenchymal stem cells were grown in 6-well plates under either muscle growth media
for non-differentiation or muscle differentiation media for differentiation conditions;
purified human IGFBP-6 recombinant protein (750 ng/ml) was added to the media only
once at the beginning of the experiment and a time course experiment was done. Cells
were lysed after 24, 48, 72 hours and 7 days and western blots were used to determine
protein levels for IGFBP-6, OCT4, and Pax3/7.
Compared to the negative control, the extracellular IGFBP-6 in either muscle growth
media or in muscle differentiation media had no significant effect on PMSC expression of
IGFBP-6 at each time point under both non-differentiation (Figure 20A) and
differentiation conditions (Figure 21A); moreover, under both conditions IGFBP-6 levels
increased over time regardless of the treatment condition.
OCT4 levels at each time point were not changed under both non-differentiation (Figure
20B) and differentiation conditions (Figure 21B). On the other hand, there was a
significant increase in Pax3/7 at day 7 with extracellular IGFBP-6 under non
differentiation conditions (Figure 20C); while there was no significant change in Pax3/7
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levels over time under differentiation conditions (Figure 21C). However, under both
conditions, IGFBP-6 levels increased over time regardless of treatment condition. This
indicates that extracellular IGFBP-6 has no significant effects on Pax3/7 levels once the
cells are committed to the muscle lineage.

F ig u r e 2 0 : C h a n g e s in I G F B P - 6 le v e ls w h e n e x tr a c e llu la r I G F B P - 6 w a s in c r e a s e d in
P M S C s u n d e r n o n -d if fe r e n t ia tio n c o n d itio n s .

Western blots were used to examine cell lysate over time in PMSCs grown in muscle
growth media after IGFBP-6 was added to the media (0.75 pg/well of recombinant
human IGFBP-6 protein); the top panel shows a representative western blot of three
independent experiments and the lower panel shows a diagram of the statistical analysis.
Extracellular IGFBP-6 had no significant effects on (A) IGFBP-6 levels, as the levels
were increased over time following both treatments, and (B) OCT4 levels; but (C)
Pax3/7 levels were significantly increased at day 7 in non-differentiation conditions
compared to control (-) IGFBP-6 (PMSCs in muscle growth media only). IGFBP-6 levels
were quantified and normalized to P-Actin. IGFBP-6 levels are presented as means and
standard error of the mean (SEM). (*) indicates comparison between the different
treatments, while (#) indicates comparison within the extracellular treatment over time,
and (a) is to compare within the control over time. (Two-way ANOVA followed by a ttest, PO.OOl, n=3).
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Figure 21: Changes with time after addition of extracellular IGFBP-6 in PMSCs
under differentiation conditions.
Quantification of IGFBP-6, OCT4 and Pax3/7 in lysates from PMSCs grown in muscle
differentiation media and treated with the addition of extracellular IGFBP-6 at the
beginning of the experiment (0.75 pg/well of recombinant human IGFBP-6 protein); the
top panel shows a representative western blot from three independent experiments and the
lower panel shows quantification and statistical analysis. Extracellular IGFBP-6 had no
significant effects on (A) IGFBP-6 levels, (B) OCT4 levels, and (C) Pax3/7 levels over
time under differentiation conditions compared to control (-) IGFBP-6 (PMSCs in muscle
differentiation media only) with an overall increase in IGFBP-6 and Pax3/7 over time
with in the same treatment.
By western blot, levels were quantified and normalized to (3-Actin. Error bars represent
the standard error of the mean (SEM). (*) indicates comparison between the different
treatments, while (#) indicates comparison within the extracellular treatment over time,
and (a) indicates comparison within the control over time. (Two-way ANOVA, P<0.001,
n=3).
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5.0 DISCUSSION
The aim of this study was to characterize the effects of IGFBP-6 on the early
differentiation of placental mesenchymal stem cells to muscle. The biologic effects of
increasing IGFBP-6, as determined by expression of markers of pluripotency (OCT4) or
commitment (Pax3/7), were more apparent under the non-differentiation conditions
before PMSCs commit to the muscle lineage, while silencing IGFBP-6 had a significant
biologic effect under both non-differentiation and differentiation conditions.
5.1 PMSCs Differentiation into Skeletal Muscle
We have demonstrated that placental mesenchymal stem cells, like other adult stem cells,
have the capacity to differentiate into muscle cells in vitro under appropriate
differentiation conditions (serum-free medium containing only lOpg/ml insulin).
Expression of differentiation markers for early muscle cells (Pax3/7) at 24, 48, and 72
hours by immunoblotting showed a two-fold increase in Pax3/7 at 3 days (Figure 9C).
Also, at 3 days post-differentiation, the expression of early muscle marker Pax3/7 was
shown using confocal microscopy (Figure 9A), as well as the presence of the multinucleation process (Figure 9B). Moreover, at 14 days post-differentiation, PMSCs
expressed late muscle differentiation markers Myogenin (Figure 9D) and MyoD (Figure
9E), as well as the formation of multi-nucleated fibers (Figure 10C). This data supports
what is known in the stem cell field, as it has been reported that under the appropriate
niche conditions, adult human mesenchymal stem cells have the capacity for myogenic
differentiation (43).
IGFBP-6 was reported to be expressed at high levels in developing muscle cells (134) and
the findings from our studies support that PMSCs express the protein in significant levels
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during differentiation. When incubated in the differentiation microenvironment, IGFBP-6
levels doubled at 3-days as demonstrated by immunoblotting (Figure 9C) and confocal
microscopy (Figure 8C).
In contrast, the pluripotency marker, OCT4, remained unchanged during differentiation
(Figure 11B). These findings indicate that IGFBP-6 is an integral protein during muscle
differentiation and that more studies are required to address why OCT4 levels are not
changing.
5.2 Increase in Intracellular IGFBP-6 in PMSCs using the Chariot™ Transport
System
Previous studies in our laboratory have indicated that the biologic role of IGFBP-6 in
muscle cells (using RD cells) is dependent on the intracellular location of IGFBP-6 either
in the cytoplasm or in the nucleus, and the intracellular effects of IGFBP-6 may be
different from its effect in the extracellular compartment. We used the Chariot™
transport system for our studies because it is non-cytotoxic, serum independent (136), and
has been tested in mammalian cells (137, 138 ), and therefore, it allows us to increase
intracellular IGFBP-6 in differentiating muscle cells and compare and contrast with the
extracellular effects of the protein during the same process. Our studies using an indicator
protein, P-galactosidase (Figure 8), demonstrated to us that the system could be used to
transport IGFBP-6 in a similar manner into PMSCs.
Our studies showed that PMSCs responded differently under non-differentiation
conditions compared to differentiation conditions. Under non-differentiation conditions
(PMSCs grown in muscle growth media), IGFBP-6 levels significantly increased at 12
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hours using Chariot™ compared to the Chariot™ control (Chariot™ complex only).
IGFBP-6 levels were stable after 12 hours until the significant increase at 7days due to
the increase in intracellular of IGFBP-6 (Figure 12A).
On the other hand, under differentiation conditions (PMSCs grown in muscle
differentiation media), there was no significant change in IGFBP-6 levels at any of the
time points (Figure 14A) indicating that IGFBP-6 intracellular increase by Chariot™ was
more effective in introducing the IGFBP-6 protein into the cell under non-differentiation
conditions before PMSCs commit to the muscle lineage.
The delivery of IGFBP-6 using Chariot™ transport system had no significant effects on
pluripotency of PMSCs as indicated by OCT4 levels under both non-differentiation
(Figure 12B) and differentiation conditions (Figure 14B). This is a novel finding due to
the fact that no studies have been performed before using Chariot™ to increase the
intracellular IGFBP-6 in PMSCs and its effects on OCT4 levels. Therefore, further
investigation is required.
5.3 IGFBP-6 on Muscle Differentiation
Increasing IGFBP-6 intracellularly using the Chariot™ System, we observed an increase
in early muscle marker Pax3/7 at 7days under non-differentiation conditions (Figure
12C), and this increase correlated with IGFBP-6 levels (Figure 12A). In contrast, under
differentiation conditions, there were no significant changes in Pax3/7 levels (Figure 14C)
correlating with IGFBP-6 levels (Figure 14A). These findings suggest that intracellular
IGFBP-6 is more effective in promoting muscle differentiation under non-differentiation
conditions before PMSCs commit to the muscle lineage. These data support previous
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reports which showed that the expression of IGFBP-6 is associated with differentiation
(82).
There was a significant increase in IGFBP-6 levels secreted to the media after treatment
with Chariot™ to increase intracellular IGFBP-6 with a significant decrease at day 7
under both non-differentiation conditions (Figure 13) as well as differentiation conditions
(Figure 15). It is expected that introduction of IGFBP-6 into the cells is associated with
an increase in the secretion of the protein into the media. However, the increase in
IGFBP-6 secretion by PMSCs was longer than expected in the cells following
introduction of the protein with Chariot treatment, suggesting that the endogenous
synthesis of IGFBP-6 may have been stimulated by the increase in intracellular IGFBP-6.
The mechanism is still unknown, and requires further studies.
5.4 Silencing IGFBP-6 under Non-differentiation and Differentiation Conditions
IGFBP-6 has a significantly greater affinity (20-100 fold), for IGF-II than IGF-I (83, 84).
Since IGF-II is present in developing placental cells in greater levels than IGF-I, the
reduction of IGFBP-6 in PMSCs would increase the proliferation effects of IGFs on the
cells as it expected that there will be a greater availability of IGF-II.
Using siRNA against IGFBP-6, there was a significant decrease in IGFBP-6 levels, a
50% decrease in IGFBP-6 levels under non-differentiation conditions (Figure 16A) and a
40% decrease under differentiation conditions (Figure 17A). The siRNA treatment was,
however, short term under both non-differentiation (Figure 16B) and differentiation
conditions (Figure 17B).
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One interesting finding was that the pluripotency marker, OCT4, decreased significantly
with IGFBP-6 silencing (Figure 16C) and (Figure 17C). The mechanism by which this
effect likely occurs is unknown and needs further investigation. Since IGFBP-6 has both
intracellular as well as extracellular effects, whether the response occurs dependent or
independent of IGFs (particularly IGF-II) has to be delineated.
The corollary finding of a significant increase in early muscle marker Pax3/7 at 24 hours
with silencing IGFBP-6 under non-differentiation conditions (Figure 16D), indicates that
reduced expression of IGFBP-6 promotes PMSCs towards the muscle differentiation
process. A significant increase in Pax3/7 levels at each time point with IGFBP-6 silencing
under differentiation conditions further supports this conclusion (Figure 17D). The
mechanism by which reduced IGFBP-6 expression leads to enhanced muscle
differentiation is unknown. The increase in Pax3/7 could be due to the presence of a
greater availability of IGF-II which is recruited to the differentiation process or could be
due to the IGFBP-6 independent actions. Future studies will delineate the underlying
mechanism.
5.5 Increased IGFBP-6 in PMSC Microenvironment
Since there was a significant decrease in IGFBP-6 levels secreted to the media after
silencing IGFBP-6 expression under both non-differentiation (Figure 18) and
differentiation conditions (Figure 19), it is also possible that the biologic effect may also
be due to an increase in extracellular action of IGF-II. However, the increase in IGFBP-6
by adding recombinant IGFBP-6 extracellularly had no effect.
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Normally, increased IGFBP-6 in the mesenchymal stem cell microenvironment is
expected to reduce the bioavailability of IGFs (especially IGF-II because of its high
affinity for the peptide). Studies in various cell lines have shown mostly an inhibitory
action of IGFBP-6 predominantly via IGF-II-dependent action. Human recombinant
IGFBP-6 has been shown to inhibit IGF-II induced myogenesis through an IGF-IIdependent mechanism in L6A1 myoblasts (135). Neuroblastoma cells undergo a decrease
both in cell proliferation and tumorigenic potency as a result of increased exogenous
IGFBP-6 (95, 96). In osteoblast cells, IGFBP-6 has also been shown to bind IGF-II and
modulate its effects on cell growth by reducing the bioavailability of IGF-II for its
receptor in the bone microenvironment (97). In human bronchial epithelial cells,
increased IGFBP-6 induces a proliferative arrest, with no evidence of apoptosis,
suggesting an inhibition of IGF-II’s ability to induce mitosis (98).
In contrast, our results show no significant effect of increased IGFBP-6 in the PMSC
microenvironment (addition of 0.75 pg/ well of purified human IGFBP-6 recombinant
protein to the media) under non-differentiation conditions on either its own expression
(Figure 20A) or OCT4 (Figure 20B). Similar effects were observed under differentiation
conditions (Figure 21 A, 21B).
The effect of increased IGFBP-6 in the cellular microenvironment on PMSC
differentiation into muscle was determined by western blot analysis for early muscle
marker Pax3/7. It showed a significant increase at day 7 under non-differentiation
conditions (Figure 20C), indicating that IGFBP-6 induces muscle differentiation even in
non-favourable conditions. This effect was not observed in differentiation conditions,
suggesting that once the PMSCs are committed into the muscle lineage, IGFBP-6 may not
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have further effect. The mechanism of action, whether IGF-dependent or -independent,
remains to be delineated.
6.0 SUMMARY AND CONCLUSIONS
To date, no previous studies have been performed relating PMSCs and IGFBP-6.
Therefore, the data presented in this thesis gives us an insight into the effects of IGFBP-6
on PMSCs. The data in this thesis demonstrate that placental mesenchymal stem cells
have the ability to differentiate into muscle cells in vitro, as identified by
immunocytochemistry and immunoblotting for early muscle marker Pax3/7 at 3days postdifferentiation, and the expression of late muscle markers Myogenin and MyoD at 14days post-differentiation using confocal imaging. PMSCs expressed IGFBP-6 as
demonstrated by immunocytochemistry and immunoblotting of muscle cells. These
findings are in agreement with previous reports of PMSCs ability to differentiate into
skeletal muscle and that IGFBP-6 may play a role in this process (44, 45, 134).
The Chariot™ method was used successfully to increase intracellular IGFBP-6. Under
non-differentiation conditions, there was an increase in Pax3/7 at day7 with no changes in
OCT4 levels. In contrast, under differentiation conditions, there were no significant
changes in IGFBP-6, Pax3/7, or OCT4. Overall, there was a correlation between IGFBP-6
levels and Pax3/7. Therefore, the effect of intracellular IGFBP-6 is more prominent under
non-differentiation conditions before PMSCs commit to the muscle lineage.
Conversely, the effect of decreasing IGFBP-6 expression using siRNA under both nondifferentiation and differentiation conditions is transient or short term with return of
IGFBP-6 to control levels by day7.
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Increasing extracellular IGFBP-6 did not cause changes to some of the parameters
analyzed, i.e. expression of IGFBP-6 or OCT4, unlike increasing the protein
intracellularly, which is different from previous reports. This could be due to the cells
used (PMSCs) or different parameters tested. Further studies are required to determine if
extracellular IGFBP-6 has any biologic actions on PMSCs.
Interestingly, there was a significant increase in IGFBP-6 levels secreted to the media
after increasing intracellular IGFBP-6 using Chariot™ and a significant decrease after
decreasing IGFBP-6 expression using siRNA.
We demonstrated that PMSCs are able to differentiate into skeletal muscle cells under
appropriate conditions, and that this process may be regulated by intracellular IGFBP-6.
Further studies are required to delineate the mechanisms of action of IGFBP-6 and IGF-II
on this biologic effect.
7.0 LIMITATIONS
•

As demonstrated in the results, PMSCs underwent differentiation even when
cultured in muscle growth media (non-differentiation media). These results needs
to be addressed more in order to fully understand why PMSCs undergo
myogenesis under non-differentiation conditions.

•

PMSCs produce their own IGFBP-6 and it is the most abundant binding protein;
therefore, there might be an interaction between the native IGFBP-6 synthesized
by the cells and the IGFBP-6 protein added exogenously.
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•

The Chariot™ system increased IGFBP-6 only transiently and is not very stable
once introduced into PMSCs. Hence, a more effective method is needed to further
study the effects of increasing the intracellular IGFBP-6 over a period of time.

•

The recombinant human IGFBP-6 used in this study is produced in E.Coli and
therefore has not undergone any post-translational processing; glycosylated
IGFBP-6 shows greater resistance to proteolysis by chymotrypsin and trypsin than
non-glycosylated IGFBP-6 (91), which raises questions about whether the effects
observed using a recombinant IGFBP-6 represent the effects of native IGFBP-6.

8.0 FUTURE STUDIES
This study provides an important foundation for future studies on the role of IGFBP-6 on
differentiation of PMSCs into muscle. Based on the data and observations in this study,
further studies can be planned as follows:
•

To study the signal transduction mechanisms of IGFBP-6 and IGF-II actions on
muscle differentiation of PMSCs (e.g., the mitogen-activated protein kinase and
the PI3K/Akt pathways) in the presence or absence of specific ERK1/2 and Akt
inhibitors.

•

To determine if IGFBP-6 effects on PMSCs are due to IGF-dependent or independent functions, we will over-express a mutant form of IGFBP-6 that does
not bind IGF-II and compare with a wild type form of IGFBP-6.

•

To determine the interaction between IGF-II and IGFBP-6 on skeletal muscle
differentiation of PMSCs.

•

To determine the level of action of IGFBP-6 on pluripotency marker (OCT4) and
muscle differentiation markers by determining the mRNA levels of OCT4.
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•

To identify further siRNAs to improve the silencing of IGFBP-6 to greater than
40-50% and to determine the biologic effects of this knockdown.

•

To determine if other pluripotency markers such as NANOG and SOX2 are
affected by intracellular or extracellular IGFBP-6.

•

To investigate the impact of IGFBP-6 and IGF-II on other biologic effects such as
proliferation and cell death (apoptosis) in addition to the differentiation events, as
they are well recognized effects of the IGF system.

9.0 SIGNIFICANCE
Knowledge of IGFBP-6 effects on muscle differentiation will help to elucidate the
mechanisms controlling stem cell fate in the presence of IGFs and improve strategies for
skeletal muscle regeneration therapies using stem cells in diseases such as muscular
dystrophy to improve muscle loss.
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